A novel in vitro pancreatic carcinogenesis model

Toxicology Letters

Volumn 202, Issue 1, 2011, Pages 15-22

  Kang, Hyo Jin ^a   Hong, Young Bin ^a   Kim, Hee Jeong ^a   Yi, Yong Weon ^a   Nath, Raghu G ^a   Chang, Young Soo ^b   Cho, Ho Chan ^c   Bae, Insoo ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Dankook University   (South Korea)

^c Dongsan Medical Center   (South Korea)

Author keywords

AhR; Benzo(a)pyrene; BRCA1; CYP1A1; Pancreatic cancer; TCDD

Indexed keywords

BENZO[A]PYRENE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; LUCIFERASE; MUTAGENIC AGENT; PHOSPHATE P 32; SMALL INTERFERING RNA;

ARTICLE; BINDING AFFINITY; CARCINOGENESIS; CELL CULTURE; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DNA ADDUCT; EPITHELIUM CELL; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RADIOACTIVITY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOBIOTIC STRESS;

ARYL HYDROCARBON HYDROXYLASES; BENZO(A)PYRENE; BRCA1 PROTEIN; CARCINOGENICITY TESTS; CARCINOGENS; CELL LINE; CYTOCHROME P-450 CYP1A1; EPITHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; RECEPTORS, ARYL HYDROCARBON; REPRESSOR PROTEINS; TETRACHLORODIBENZODIOXIN; XENOBIOTICS;

EID: 79952042366     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.01.012     Document Type: Article

References (57)

1. Agency for Toxic Substances and Disease Registry, Division of Toxicology/Toxicology Information Branch Toxicological Profile for Chlorinated Dibenzo-p-Dioxins 1998, Public Health Service, U.S. Department of Health and Human Services, Atlanta, GA.
2. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
3. Al-Sukhni W., Rothenmund H., Eppel Borgida A., Zogopoulos G., O'Shea A.M., Pollett A., Gallinger S. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum. Genet. 2008, 124:271-278.
4. Andersson P., McGuire J., Rubio C., Gradin K., Whitelaw M.L., Pettersson S., Hanberg A., Poellinger L. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9990-9995.
5. Arlt V.M., Stiborová M., Henderson C.J., Thiemann M., Frei E., Aimová D., Singh R., Gamboa da Costa G., Schmitz O.J., Farmer P.B., Wolf C.R., Phillips D.H. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 2008, 29:656-665.
6. Bae I., Fan S., Meng Q., Rih J.K., Kim H.J., Kang H.J., Xu J., Goldberg I.D., Jaiswal A.K., Rosen E.M. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 2004, 64:7893-7909.
7. Beger C., Ramadani M., Meyer S., Leder G., Krüger M., Welte K., Gansauge F., Beger H.G. Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma. Clin. Cancer Res. 2004, 10:3780-3787.
8. Burke M.D., Mayer R.T. Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation, which is preferentially inducible by 3-methylcholanthrene. Drug Metab. Dispos. 1974, 2:583-588.
9. Caldas C., Hahn S.A., da Costa L.T., Redston M.S., Schutte M., Seymour A.B., Weinstein C.L., Hruban R.H., Yeo C.J., Kern S.E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 1994, 8:27-32.
10. Davarinos N.A., Pollenz R.S. Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytosplasmic proteasome following nuclear export. J. Biol. Chem. 1999, 274:28708-28715.
11. Denison M.S., Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43:309-334.
12. Dolwick K.M., Schmidt J.V., Carver L.A., Swanson H.I., Bradfield C.A. Cloning and expression of a human Ah receptor cDNA. Mol. Pharmacol. 1993, 44:911-917.
13. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005, 7:60.
14. Furukawa T., Duguid W.P., Rosenberg L., Viallet J., Galloway D.A., Tsao M.S. Long term culture and immortalization of epithelial cells from normal adult human pancreatic ducts by transfection with the E6E7 gene of human papilloma virus 16. Am. J. Pathol. 1996, 148:1763-1770.
15. Goggins M., Schutte M., Lu J., Weinstein C.L., Petersen G.M., Yeo C.J., Jackson C.E., Lynch H.T., Hruban R.H., Kern S.E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996, 56:5360-5364.
16. Hankinson O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 1995, 35:307-340.
17. Hartman A.R., Ford J.M. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 2002, 32:180-184.
18. Huxley R., Ansary-Moghaddam A., Berrington de González A., Barzi F., Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 2005, 92:2076-2083.
19. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
20. Kang H.J., Kim H.J., Cho C.H., Hu Y., Li R., Bae I. BRCA1 transcriptional activity is enhanced by interactions between its AD1 domain and AhR. Cancer Chemother. Pharmacol. 2008, 62:965-975.
21. Kang H.J., Kim H.J., Kim S.K., Barouki R., Cho C.H., Khanna K.K., Rosen E.M., Bae I. BRCA1 modulates xenobiotic stress inducible gene expression by interacting with ARNT in human breast cancer cells. J. Biol. Chem. 2006, 281:14654-14662.
22. Kang H.J., Kim H.J., Kwon S.H., Kang B.D., Eling T.E., Lee S.H., Bae I. BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity. Cancer Chemother. Pharmacol. 2008, 62:689-697.
23. Kang H.J., Kim H.J., Rih J.K., Mattson T.L., Kim K.W., Cho C.H., Isaacs J.S., Bae I. BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J. Biol. Chem. 2006, 281:13047-13056.
24. Kang S.C., Lee B.M. Effect of estrogen receptor (ER) on benzo[a]pyrene-DNA adduct formation in human breast cancer cells. J. Toxicol. Environ. Health A 2005, 68:1833-1840.
25. Kang S.P., Saif M.W. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP 2008, 9:251-266.
26. Karchner S.I., Jenny M.J., Tarrant A.M., Evans B.R., Kang H.J., Bae I., Sherr D.H., Hahn M.E. The active form of human aryl hydrocarbon receptor (AHR) repressor lacks exon 8, and its Pro 185 and Ala 185 variants repress both AHR and hypoxia-inducible factor. Mol. Cell. Biol. 2009, 29:3465-3477.
27. Kim R., Saif M.W. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?. JOP 2007, 8:279-288.
28. Kondraganti S.R., Fernandez-Salguero P., Gonzalez F.J., Ramos K.S., Jiang W., Moorthy B. Polycyclic aromatic hydrocarbon-inducible DNA adducts: evidence by 32P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo. Int. J. Cancer 2003, 103:5-11.
29. Koorstra J.B., Hustinx S.R., Offerhaus G.J., Maitra A. Pancreatic carcinogenesis. Pancreatology 2008, 8:110-125.
30. Lin Y., Tamakoshi A., Kawamura T., Inaba Y., Kikuchi S., Motohashi Y., Kurosawa M. A prospective cohort study of cigarette smoking and pancreatic cancer in Japan. Cancer Causes Control 2002, 13:249-254. JACC Study Group, Japan Collaborative Cohort.
31. Lowenfels A.B., Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20:197-209.
32. Lynch H.T., Deters C.A., Snyder C.L., Lynch J.F., Villeneuve P., Silberstein J., Martin H., Narod S.A., Brand R.E. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet. Cytogenet. 2005, 158:119-125.
33. Mai P.L., Chatterjee N., Hartge P., Tucker M., Brody L., Struewing J.P., Wacholder S. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS One 2009, 4:e4812.
34. Michaud D.S., Giovannucci E., Willett W.C., Colditz G.A., Stampfer M.J., Fuchs C.S. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286:921-929.
35. Michaud D.S., Liu S., Giovannucci E., Willett W.C., Colditz G.A., Fuchs C.S. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J. Natl. Cancer Inst. 2002, 94:1293-1300.
36. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
37. Moennikes O., Loeppen S., Buchmann A., Andersson P., Ittrich C., Poellinger L., Schwarz M. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 2004, 64:4707-4710.
38. Motykiewicz G., Faraglia B., Wang L.W., Terry M.B., Senie R.T., Santella R.M. Removal of benzo(a)pyrene diol epoxide (BPDE)-DNA adducts as a measure of DNA repair capacity in lymphoblastoid cell lines from sisters discordant for breast cancer. Environ. Mol. Mutagen. 2002, 40:93-100.
39. Nakata K., Tanaka Y., Nakano T., Adachi T., Tanaka H., Kaminuma T., Ishikawa T. Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems. Drug Metab. Pharmacokinet. 2006, 21:437-457.
40. National Toxicology Program NTP toxicology and carcinogenesis studies of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (CAS No. 57117-31-4), and 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female harlan Sprague-Dawley rats (Gavage Studies). Natl. Toxicol. Program Tech. Rep. Ser. 2006, 526:1-180.
41. Ouyang H., Mou L., Luk C., Liu N., Karaskova J., Squire J., Tsao M.S. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am. J. Pathol. 2000, 157:1623-1631.
42. Pan J., Davis W., Trushin N., Amin S., Nath R.G., Salem N., Chung F.L. A solid-phase extraction/high-performance liquid chromatography-based 32P-postlabeling method for detection of cyclic 1, N(2)-propanodeoxyguanosine adducts derived from enals. Anal. Biochem. 2006, 348:15-23.
43. Phillips D.H., Arlt V.M. The 32P-postlabeling assay for DNA adducts. Nat. Protocols 2007, 2:2772-2781.
44. Qian J., Niu J., Li M., Chiao P.J., Tsao M.S. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res. 2005, 65:5045-5053.
45. Redston M.S., Caldas C., Seymour A.B., Hruban R.H., da Costa L., Yeo C.J., Kern S.E. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994, 54:3025-3033.
46. Shimada T., Inoue K., Suzuki Y., Kawai T., Azuma E., Nakajima T., Shindo M., Kurose K., Sugie A., Yamagishi Y., Fujii-Kuriyama Y., Hashimoto M. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis 2002, 23:1199-1207.
47. Shimizu Y., Nakatsuru Y., Ichinose M., Takahashi Y., Kume H., Mimura J., Fujii-Kuriyama Y., Ishikawa T. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:779-782.
48. Silverman D.T., Dunn J.A., Hoover R.N., Schiffman M., Lillemoe K.D., Schoenberg J.B., Brown L.M., Greenberg R.S., Hayes R.B., Swanson G.M. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J. Natl. Cancer Inst. 1994, 86:1510-1516.
49. Skog K. Cooking procedures and food mutagens: a literature review. Food Chem. Toxicol. 1993, 31:655-675.
50. Starita L.M., Parvin J.D. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr. Opin. Cell Biol. 2003, 15:345-350.
51. Sugimura T., Nagao M., Wakabayashi K. Heterocyclic amines in cooked foods: candidates for causation of common cancers. J. Natl. Cancer Inst. 1994, 86:2-4.
52. Uno S., Dalton T.P., Derkenne S., Curran C.P., Miller M.L., Shertzer H.G., Nebert D.W. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol. Pharmacol. 2004, 65:1225-1237.
53. Watanabe T., Imoto I., Kosugi Y., Fukuda Y., Mimura J., Fujii Y., Isaka K., Takayama M., Sato A., Inazawa J. Human arylhydrocarbon receptor repressor (AHRR) gene: genomic structure and analysis of polymorphism in endometriosis. J. Hum. Genet. 2001, 46:342-346.
54. Whitlock J.P. Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 1999, 39:103-125.
55. Xu C., Li C.Y., Kong A.T. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28:249-268.
56. Yamamoto J., Ihara K., Nakayama H., Hikino S., Satoh K., Kubo N., Iida T., Fujii Y., Hara T. Characteristic expression of aryl hydrocarbon receptor repressor gene in human tissues: organ-specific distribution and variable induction patterns in mononuclear cells. Life Sci. 2004, 74:1039-1049.
57. Zudaire E., Cuesta N., Murty V., Woodson K., Adams L., Gonzalez N., Martínez A., Narayan G., Kirsch I., Franklin W., Hirsch F., Birrer M., Cuttitta F. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J. Clin. Invest. 2008, 118:640-650.